{"DataElement":{"publicId":"6635878","version":"1","preferredName":"Treatment Cohort Study 10208 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10208 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10208_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6635865","version":"1","preferredName":"EC10208 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6635865v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ARM3DL2","valueDescription":"ARM3DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Gemcitab 1000 mg/m2 IV d1 & 8","ValueMeaning":{"publicId":"6635866","version":"1","preferredName":"ARM3DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Gemcitab 1000 mg/m2 IV d1 & 8","longName":"6635866","preferredDefinition":"ARM3DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Gemcitab 1000 mg/m2 IV d1 & 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DA00-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DA19-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM3DL1","valueDescription":"ARM3DL1: Cycle 1 Anetumab 5.5 mg/kg IV d, Nivol 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1,  Gemcitab 1000 mg/m2 IV D1 & 8","ValueMeaning":{"publicId":"6635867","version":"1","preferredName":"ARM3DL1: Cycle 1 Anetumab 5.5 mg/kg IV d, Nivol 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1,  Gemcitab 1000 mg/m2 IV D1 & 8","longName":"6635867","preferredDefinition":"ARM3DL1: Cycle 1 Anetumab 5.5 mg/kg IV d, Nivol 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1& 8; Cycles 2+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1,  Gemcitab 1000 mg/m2 IV D1 & 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DA23-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DA3C-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM3DL-1","valueDescription":"ARM3DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1 & 8; Cycles 2+ Anetumab 4.5 mg/kg IV d1, Nivo360 mg IV d1,  Gemcitab 1000 mg/m2 IV d1 & 8","ValueMeaning":{"publicId":"6635868","version":"1","preferredName":"ARM3DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1 & 8; Cycles 2+ Anetumab 4.5 mg/kg IV d1, Nivo360 mg IV d1,  Gemcitab 1000 mg/m2 IV d1 & 8","longName":"6635868","preferredDefinition":"ARM3DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Gemcitab 1000 mg/m2 IV d1 & 8; Cycles 2+ Anetumab 4.5 mg/kg IV d1, Nivo360 mg IV d1,  Gemcitab 1000 mg/m2 IV d1 & 8","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DA46-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DA5F-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM2DL2","valueDescription":"ARM2DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635869","version":"1","preferredName":"ARM2DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1","longName":"6635869","preferredDefinition":"ARM2DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 6.5 mg/kg IV d1, Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DA69-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DA82-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM2DL1","valueDescription":"ARM2DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 5.5 mg/kg IV d1, Nivo360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635870","version":"1","preferredName":"ARM2DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 5.5 mg/kg IV d1, Nivo360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1","longName":"6635870","preferredDefinition":"ARM2DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 5.5 mg/kg IV d1, Nivo360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5.5 mg/kg IV d1, Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DA8C-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DAA5-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM2DL-1","valueDescription":"ARM2DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5 mg/kg IV d, Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635871","version":"1","preferredName":"ARM2DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5 mg/kg IV d, Nivo 360 mg IV d1","longName":"6635871","preferredDefinition":"ARM2DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d8, Ipi 1mg/kg IV d8; Cycles 2-4 Anetumab 4.5 mg/kg IV d1, Nivo 360 mg IV d1, Ipi 1mg/kg IV d1; Cycles 5+ Anetumab 5 mg/kg IV d, Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DAAF-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DAC8-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM1DL2","valueDescription":"ARM1DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d8;  Cycles 2+ Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635872","version":"1","preferredName":"ARM1DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d8;  Cycles 2+ Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d1","longName":"6635872","preferredDefinition":"ARM1DL2: Cycle 1 Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d8;  Cycles 2+ Anetumab 6.5 mg/kg IV d1 & Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DAD2-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DAEB-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM1DL1","valueDescription":"ARM1DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 5.5 mg/kg IV d1& Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635873","version":"1","preferredName":"ARM1DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 5.5 mg/kg IV d1& Nivo 360 mg IV d1","longName":"6635873","preferredDefinition":"ARM1DL1: Cycle 1 Anetumab 5.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 5.5 mg/kg IV d1& Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DAF5-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DB0E-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"},{"value":"ARM1DL-1","valueDescription":"ARM1DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d1","ValueMeaning":{"publicId":"6635874","version":"1","preferredName":"ARM1DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d1","longName":"6635874","preferredDefinition":"ARM1DL-1: Cycle 1 Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d8; Cycles 2+ Anetumab 4.5 mg/kg IV d1 & Nivo 360 mg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-DB18-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8140D9AB-DB31-6998-E053-F662850A08DD","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"ONEDATA","dateModified":"2019-02-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8140D9AB-D9E8-6998-E053-F662850A08DD","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeDescription":"2/7/19 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Treatment Cohort","type":"Preferred Question Text","description":"Treatment Cohort","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Please select a cohort","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8141EE99-86D2-15E1-E053-F662850A3D67","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}